Immunotherapies

Immunotherapies

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor,...
Cancer Journey:
Cancer Type:
For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our...
Cancer Journey:
Cancer Type:
Disease Learning:
For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our...
Cancer Journey:
Cancer Type:
Disease Learning:
For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our...
Cancer Journey:
Cancer Type:
Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate...
Cancer Journey:
Cancer Type:

Articles

Download slides from LIVE WEBCAST of November 18, 2017 in partnership with Georgetown University Hospital, GRACE presents: 2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know
Cancer Journey:
Cancer Type:
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
Cancer Journey:
Cancer Type:
Several weeks ago, at a very crowded plenary session for the European Society of Medical Oncology (ESMO) in Copenhagen, Denmark, results with first...
Cancer Journey:
Cancer Type:
Disease Learning:
Among the many novel concepts in managing immunotherapy is the potential for “pseudo-progression”. This unusual phenomenon is when a patient’s scans...
Cancer Journey:
Cancer Type:
It seemed inevitable, I think. Several immuntherapy agents known as PD-1 or PD-L1 checkpoint inhibitors have been shown to lead to better survival,...
Cancer Journey:
Cancer Type:
Disease Learning:

Community Forum

On Saturday, November 10, 2018, GRACE partnered with Swedish Cancer Institute to present a live and webcast discussion on Local Therapies for...
Cancer Journey:
Cancer Type:
Progression after 3 1/2 years on Tarceva. Tissue biopsy showed T790m negative. Any suggestions/experience on next steps? Onc suggesting I move to Afatinib or a Opdivo. PDL1 was tested and is <1%.
Cancer Journey:
Cancer Type:
Hello friends, My mom, (aged 77, Adenocarcinoma NSCLC, Stage 4, EGFR and ALK negative) was diagnosed in 2014, underwent VATS and pleurodesis,...
Cancer Journey:
Cancer Type:
Hi Grace community, Thank you for the extensive information and great support on your website. It seems that after 9,5 years I have developed...
Cancer Journey:
Cancer Type: